Metsera's IPO raised $316.2 million, funding its obesity drug MET-097i, which shows promise with once-monthly dosing. Read ...

A Quick Take On Metsera, Inc. Metsera, Inc. (NASDAQ:MTSR) has filed to raise $275 million in an IPO of its common stock, according to SEC S-1/A registration information. The firm is a clinical ...

Guggenheim analyst sees significant upside in Metsera stock to $56. MTSR is working on both injectable and oral weight-loss ...

At the closing bell, Metsera’s stock MTSR stood at $26.50, well above its IPO pricing level of $18. It opened on the Nasdaq at $25.50. Back To Top ...

Last September, another obesity-focused biotech, BioAge, completed an upsized IPO that raised $198 million, after the number of shares on offer was hiked by 40%. Metsera's lead asset is MET-097i ...

Investing.com -- Wall Street analysts initiated coverage on Metsera with bullish outlook given the biotech firm’s ...

Guggenheim initiated coverage of Metsera (MTSR) with a Buy rating and $56 price target The firm sees a “highly promising multi-billion ...

Metsera and Maze Therapeutics have become the second and third biotechs to complete an initial public offering (IPO) on the Nasdaq this year, raising $275 million and $140 million, respectively.

Metsera is engaged in the development of injectable ... The company raised $257 million during its IPO, pricing shares above its targeted range. Currently, the stock is trading at $32.08 per ...

At the closing bell, Metsera's stock (MTSR) stood at $26.50, well above its IPO pricing level of $18. It opened on the Nasdaq at $25.50. Infinity Natural Resources (INR) ended its first day of ...